Treatment with the oral diabetes drug dapagliflozin (a member of the class of medicines known as SGLT2 inhibitors) for 24 weeks improves blood glucose control in people with type 1 diabetes, according to a new study in Diabetes Care.
For the research, roughly 1,600 people with inadequately controlled type 1 diabetes received 5-milligram or 10-milligram doses of dapagliflozin or placebo (inactive treatment). The researchers found that those receiving dapagliflozin experienced improved average blood glucose levels, time in range and blood glucose variability.
“The reduced variability reported here suggests that treatment with dapagliflozin along with adjustable insulin may improve treatment adherence and reduce the risk of complications in people with type 1 diabetes,” the researchers noted.
The European Commission recently approved dapagliflozin for use as an adjunct treatment in type 1 diabetes in certain adults, and the medicine is currently under review in the United States for use along with insulin in type 1 diabetes.
Want to learn more about dapagliflozin and other members of this drug class? Read “Diabetes Medicines: SGLT2 Inhibitors.”
